Literature DB >> 18401297

Retinal detachment: visual acuity and subretinal immunoreactive endothelin-1.

M Roldán-Pallarés1, A Sadiq-Musa, R Rollin, C Bravo-Llatas, A Fernández-Cruz, R Fernández-Durango.   

Abstract

PURPOSE: To analyze whether subretinal (SRF) endothelin-1 (ET-1) - a vasoactive, mitogenic, and pro-apoptotic peptide - levels are related to visual acuity (VA) in rhegmatogenous retinal detachment (RD). PATIENTS AND METHODS: Sixty-six healthy patients between 42 and 70 years of age with unilateral RD, all candidates for scleral buckling surgery (PVR<C3) as a first and single surgical procedure, were prospectively selected. Using radioimmunoassay, immunoreactive ET-1 (IR-ET-1) was tested in both plasma and subretinal fluid (SRF) of these retinal detachment (RD) patients. Best-corrected Snellen VA was considered before surgery (preoperative) and 8 months after surgery (postoperative). Pearson correlations were made between IR-ET-1 levels (in plasma and SRF) and VA (preoperative, postoperative, and postoperative minus preoperative difference).
RESULTS: Mean IR-ET-1 values were plasma, 2.91+/-0.44 pg/ml, and SRF, 10.71+/-7.95 pg/ml. Mean VA values were preoperative VA, 0.31+/-0.16; postoperative VA, 0.66+/-0.29; and VA difference, 0.35+/-0.18. Plasma IR-ET-1 showed significant (p<0.0001) negative linear correlations with preoperative VA (r=-0.52), postoperative VA (r=-0.69), and VA difference (r=-0.65). SRF IR-ET-1 showed significant (p<0.0001) negative linear correlations with preoperative VA (r=-0.48), postoperative VA (r=-0.61), and VA difference (r=-0.54). When proliferative vitreoretinopathy (PVR) was associated with RD, correlations between SRF IR ET-1 and postoperative VA (r=-0.70) and VA difference (r=-0.75) showed the highest negative values
CONCLUSIONS: Correlations between SRF IR-ET-1 and VA were negative and higher for postoperative VA and these correlations showed the highest values when RD was associated with PVR. These findings support the idea of doing primary vitrectomy and perhaps using coadjutant pharmacologic therapy in these cases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18401297     DOI: 10.1016/s0181-5512(08)70328-0

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  6 in total

1.  Preoperative duration of retinal detachment and preoperative central retinal artery hemodynamics: repercussion on visual acuity.

Authors:  Manuela Roldán-Pallarés; Abdalla-Sadiq Musa; Julián Hernández-Montero; Carmen Bravo-Llatas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-01-21       Impact factor: 3.117

2.  Modelling postoperative visual acuity with and without proliferative vitreoretinopathy associated with primary rhegmatogenous retinal detachment.

Authors:  M Roldán-Pallarés; C Bravo-Llatas; A-S Musa; J Hernandez-Montero; R Fernández-Durango
Journal:  Eye (Lond)       Date:  2012-08-10       Impact factor: 3.775

3.  Preoperative duration of retinal detachment and subretinal immunoreactive endothelin-1: repercussion on logarithmic visual acuity.

Authors:  Manuela Roldán-Pallarès; Abdalla-Sadiq Musa; Carmen Bravo-Llatas; Raquel Fernández-Durango
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-09-25       Impact factor: 3.117

4.  Endothelin-1 role in human eye: a review.

Authors:  Serena Salvatore; Enzo Maria Vingolo
Journal:  J Ophthalmol       Date:  2011-03-03       Impact factor: 1.909

5.  Biomarkers for PVR in rhegmatogenous retinal detachment.

Authors:  Souska Zandi; Isabel B Pfister; Peter G Traine; Christoph Tappeiner; Alain Despont; Robert Rieben; Magdalena Skowronska; Justus G Garweg
Journal:  PLoS One       Date:  2019-04-03       Impact factor: 3.240

6.  Changes in Retinal Vessel and Retinal Layer Thickness After Vitrectomy in Retinal Detachment via Swept-Source OCT Angiography.

Authors:  Eun Hee Hong; Heeyoon Cho; Du Roo Kim; Min Ho Kang; Yong Un Shin; Mincheol Seong
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-02-07       Impact factor: 4.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.